Oppenheimer Reiterates Outperform Rating on Xeris Pharmaceuticals (XERS)

September 10, 2026 6:11 AM

Oppenheimer analyst Leland Gershell reiterated an Outperform rating and $18.00 price target on Xeris Pharmaceuticals (NASDAQ: XERS).The analyst commented: "Yesterday's ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found